We read the report by Mecoli et al on the relationship between cancer and anti-Th/To antibodies (AThAs) in patients with systemic sclerosis (SSc) (1). It is interesting that the presence of AThAs was reported to confer a protective effect against cancer development in those patients. However, cancer development in AThA-positive patients was significantly suppressed only within the first 3 years after SSc onset, and there was no significant difference in the number of deceased between the AThA-positive and AThA-negative patients.

中文翻译：

---

抗 Th/To 抗体阳性系统性硬化症患者发生癌症的长期风险：评论 Mecoli 等人的文章。

我们阅读了 Mecoli 等人关于系统性硬化症 (SSc) 患者癌症与抗 Th/To 抗体 (AThAs) 之间关系的报告 (1)。有趣的是，据报道 AThA 的存在对这些患者的癌症发展具有保护作用。然而，AThA 阳性患者的癌症发展仅在 SSc 发病后的前 3 年内受到显着抑制，并且 AThA 阳性和 AThA 阴性患者的死亡人数没有显着差异。